WO2011083391A3 - Biomarqueurs pour une thérapie du cancer par un anti-igf-1r - Google Patents

Biomarqueurs pour une thérapie du cancer par un anti-igf-1r Download PDF

Info

Publication number
WO2011083391A3
WO2011083391A3 PCT/IB2010/056071 IB2010056071W WO2011083391A3 WO 2011083391 A3 WO2011083391 A3 WO 2011083391A3 IB 2010056071 W IB2010056071 W IB 2010056071W WO 2011083391 A3 WO2011083391 A3 WO 2011083391A3
Authority
WO
WIPO (PCT)
Prior art keywords
igf
biomarkers
cancer therapy
therapy
cancer
Prior art date
Application number
PCT/IB2010/056071
Other languages
English (en)
Other versions
WO2011083391A2 (fr
Inventor
Stephanie Janet Green
Antonio Gualberto
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of WO2011083391A2 publication Critical patent/WO2011083391A2/fr
Publication of WO2011083391A3 publication Critical patent/WO2011083391A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4745—Insulin-like growth factor binding protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La présente invention porte sur l'utilisation d'IGF-1 libre, et du rapport insuline/IGFBP dans le sang, en tant que biomarqueurs pour une thérapie du cancer par un antagoniste de l'IGF-1R, ainsi que sur un procédé pour le traitement du cancer par une thérapie du cancer utilisant l'IGF-1 R chez des patients choisis sur la base de ces biomarqueurs.
PCT/IB2010/056071 2010-01-05 2010-12-24 Biomarqueurs pour une thérapie du cancer par un anti-igf-1r WO2011083391A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29247110P 2010-01-05 2010-01-05
US61/292,471 2010-01-05

Publications (2)

Publication Number Publication Date
WO2011083391A2 WO2011083391A2 (fr) 2011-07-14
WO2011083391A3 true WO2011083391A3 (fr) 2011-09-01

Family

ID=43920382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/056071 WO2011083391A2 (fr) 2010-01-05 2010-12-24 Biomarqueurs pour une thérapie du cancer par un anti-igf-1r

Country Status (2)

Country Link
JP (1) JP2011141279A (fr)
WO (1) WO2011083391A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
WO2023276869A1 (fr) * 2021-06-28 2023-01-05 学校法人 久留米大学 Procédé de prédiction d'un pronostic après traitement avec un inhibiteur d'angiogenèse, et multithérapie anticancéreuse

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (fr) * 2001-01-05 2002-07-11 Pfizer Inc. Anticorps anti-recepteur du facteur de croissance insulinoide i
US20050214826A1 (en) * 2004-02-19 2005-09-29 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2007141626A1 (fr) * 2006-06-02 2007-12-13 Pfizer Products Inc. Analyse de cellules tumorales circulantes

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996037777A1 (fr) 1995-05-23 1996-11-28 Nelson Randall W Immuno-dosage spectrometrique de masse
EP1349574A2 (fr) 2001-01-09 2003-10-08 MERCK PATENT GmbH Polytherapie faisant appel a des inhibiteurs de recepteurs tyrosine kinase et a des inhibiteurs d'angiogenese
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
JP4606739B2 (ja) 2002-01-18 2011-01-05 ピエール、ファーブル、メディカマン 新規抗ｉｇｆ−ｉｒ抗体およびその使用
WO2003100008A2 (fr) 2002-05-24 2003-12-04 Schering Corporation Anticorps anti-igfr humain neutralisant
GB0226370D0 (en) 2002-11-12 2002-12-18 Novartis Ag Organic compounds
SE0203746D0 (sv) 2002-12-18 2002-12-18 Karolinska Innovations Ab New compounds
JP4473257B2 (ja) 2003-04-02 2010-06-02 エフ．ホフマン−ラ ロシュ アーゲー インスリン様成長因子ｉ受容体に対する抗体及びその使用
WO2005016970A2 (fr) 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
WO2005097800A1 (fr) 2004-04-02 2005-10-20 Osi Pharmaceuticals, Inc. Inhibiteurs de la proteine kinase heterobicycliques a substitution de noyau bicyclique 6,6
EP1827487A2 (fr) 2004-11-17 2007-09-05 Board of Regents, The University of Texas System Immunotherapie de cancer impliquant p53
EP1841760B1 (fr) 2004-12-30 2011-08-10 Exelixis, Inc. Dérivés de pyrimidine en tant que modulateurs de kinase et méthodes d'emploi
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
US20080194596A1 (en) 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
US8324194B2 (en) 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
KR20080113268A (ko) 2006-03-28 2008-12-29 바이오겐 아이덱 엠에이 인코포레이티드 항 ｉｇｆ-1ｒ 항체 및 그의 용도
JP5185930B2 (ja) 2006-07-07 2013-04-17 ブリストル−マイヤーズ スクイブ カンパニー ピロロトリアジンキナーゼ阻害剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (fr) * 2001-01-05 2002-07-11 Pfizer Inc. Anticorps anti-recepteur du facteur de croissance insulinoide i
US20050214826A1 (en) * 2004-02-19 2005-09-29 Yale University Identification of cancer protein biomarkers using proteomic techniques
WO2007141626A1 (fr) * 2006-06-02 2007-12-13 Pfizer Products Inc. Analyse de cellules tumorales circulantes

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUALBERTO A. ET AL.: "1006 The anti-IGF-IR antibody figitumumab (CP-751,871) is active in patients with lung adenocarcinoma undergoing epithelial-tomesenchymal transition", EUR. J. CANCER SUPPLEMENTS, vol. 7, no. 2, September 2009 (2009-09-01), pages 88 - 89, XP026560258 *
GUALBERTO A. ET AL.: "Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions", ONCOGENE, vol. 28, no. 34, 27 August 2009 (2009-08-27), pages 3009 - 3021, XP002636347 *
GUALBERTO A. ET AL.: "Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab", BRIT. J. CANCER, vol. 104, no. 1, 4 January 2011 (2011-01-04), pages 68 - 74, XP002636348 *
KARP D.D. ET AL.: "Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer", J. CLIN. ONCOL., vol. 27, no. 15, 20 May 2009 (2009-05-20), pages 2516 - 2522, XP002636346 *
KARP D.D. ET AL.: "Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin", J. THORAC. ONCOL., vol. 4, no. 11, November 2009 (2009-11-01), pages 1397 - 1403, XP002636345 *

Also Published As

Publication number Publication date
WO2011083391A2 (fr) 2011-07-14
JP2011141279A (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
CA2909335C (fr) Fenfluramine destinee a etre utilisee pour le traitement du syndrome de dravet
GB201020860D0 (en) Disulfiram formulation and uses thereof
WO2011112953A3 (fr) Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples négatifs et de type basal
MX2014015423A (es) Analogos de peptido de exedina-4.
EP2692366A4 (fr) Instrument médical pourvu d'une couche de revêtement coulissante, et seringue
EP3052131A4 (fr) Procédés de traitement du cancer chez des patients présentant des taux élevés de bim
WO2010083385A3 (fr) Composés permettant de réduire la résistance aux médicaments et leurs utilisations
EP2563426A4 (fr) Application à cisaillement élevé utilisée dans une thérapie médicale
MX2015001716A (es) Niclosamida para el tratamiento de tumores solidos.
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2013071056A3 (fr) Polythérapie médicamenteuse pour le traitement de tumeurs solides
BR112013002441A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição e método de tratamento de paciente que sofre de câncer
HK1185808A1 (zh) 用於治療癌症的包含威羅菲尼和干擾素的組合療法
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
MX2013006319A (es) Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek.
EP3016607A4 (fr) Systèmes et procédés pour l'irradiation in vivo de sang
WO2015001013A3 (fr) Anticorps anti-ifn-alpha humains
IL207722A (en) Pyridopyrazinone Derivatives as Insulators, Methods of Preparation and Use for Diabetes
WO2012082821A3 (fr) Traitements de mélanomes
WO2011085134A3 (fr) Méthodes et compositions pour le diagnostic, le pronostic et le traitement du cancer
WO2011083391A3 (fr) Biomarqueurs pour une thérapie du cancer par un anti-igf-1r
WO2011163512A3 (fr) Traitement anticancéreux
WO2014026013A3 (fr) Méthodes destinées à préserver ou à améliorer la santé, le bien-être et/ou une fonction physiologique chez un sujet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10816423

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10816423

Country of ref document: EP

Kind code of ref document: A2